3-antigen Hepatitis B Vaccine Reports Positive Early 2024 Results

A newly approved vaccine option for protecting adults from hepatitis B (HepB) reported positive news.

Today, VBI Vaccines Inc. provided a business update that included the PreHevbrio™ (PreHevbri®, Sci-B-Vac®) vaccine and announced financial results for the year that ended December 31, 2023.

The U.S. sales volume totaled approximately 65% of the 2023 full-year volume.

The Company stated preliminary 2024 PreHevbrio U.S. sales demonstrate a substantial outpacing of 2023 on a volume basis through early March 2024.

Market segment contracting platforms continue to see growth across large hospital systems, national and regional pharmacy networks, multiple extensive military and federal facilities, prisons, and independent and public health clinics:

A top-five national health system converted to PreHevbrio in early 2024, with contracting efforts underway to secure additional partners

Retail usage is supported by strong ordering from national chains, including Walmart and regional pharmacy networks

Additionally, PreHevbrio is also available for purchase through the CDC Adult Vaccine Contract

“Over the last 12 months, we’ve seen continued progress across all of our lead programs – with increased use of PreHevbrio and an ever-expanding access and distribution network in place, as well as positive clinical data announcements from all lead pipeline programs, we are helping to make great strides in the fight against GBM, hepatitis B, and coronaviruses,” said Jeff Baxter, VBI’s President and CEO, in a press release on April 16, 2024.

As of April 2024, PreHevbri is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of HepB approved for use by the FDA in the United States